The latest mania: selling bipolar disorder - PubMed (original) (raw)

Review

The latest mania: selling bipolar disorder

David Healy. PLoS Med. 2006 Apr.

Erratum in

Abstract

Healy analyzes the surge in diagnoses of bipolar disorder and the evidence on the effectiveness of antipsychotic drugs and anticonvulsants in prophylaxis against the disorder.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: DH has been a speaker, consultant, or clinical trialist for Lilly, Janssen, SmithKline Beecham, Pfizer, Astra-Zeneca, Lorex-Synthelabo, Lundbeck, Organon, Pierre-Fabre, Roche, and Sanofi. He has also been an expert witness in ten legal cases involving antidepressants and suicide or homicide and one case involving the patent on olanzapine (Zyprexa). None of these interests played any part in the submission or preparation of this paper.

Figures

Figure 1

Figure 1. Articles Elicited by Medline Using the Mesh Term “Mood Stabilizer”

Figure 2

Figure 2. Author's Graph of _p_-Value Function Based on Data in [ 30]

(Illustration: Sapna Khandwala)

Comment in

References

    1. Moynihan R, Cassels A. Selling sickness. New York: Nation Books; 2005. 254 pp.
    1. Tohen M, Calabrese JR, Sachs G, Banov MD, Detke HC, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006;163:247–256. -PubMed
    1. Healy D. The antidepressant era. Cambridge (Massachusetts): Harvard University Press; 1997. 317 pp.
    1. Department of Health and Human Services. NDA 20-320: Depakote. Proceedings of the 44th Psychopharmacologic Drugs Advisory Committee Meeting; 6 February 1995; Washington (D. C.). 1995.
    1. Sachs G. Bipolar mood disorder: Practical strategies for acute and maintenance phase treatment. J Clin Psychopharmacol. 1996;16:32s–47s. -PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources